

Appl. No. : **10/719,619**
Filed : **November 20, 2003**

AMENDMENTS TO THE CLAIMS

1-89. (Canceled).

90. (New) A method of increasing the titer of hepatitis viral antigen-specific IgG antibodies in a subject in need thereof consisting essentially of providing, in a single administration, an immunogenic composition that comprises an effective amount of ribavirin and said hepatitis viral antigen to said subject.

91. (New) The method of Claim 90, further comprising identifying said subject as one in need of an increase in titer of IgG antibodies that are specific for said hepatitis viral antigen.

92. (New) The method of Claim 90, further comprising measuring the increase in the titer of hepatitis viral antigen-specific IgG antibodies in a subject.

93. (New) The method of Claim 91, further comprising measuring the increase in the titer of hepatitis viral antigen-specific IgG antibodies in said subject.

94. (New) The method of Claim 90, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

95. (New) The method of Claim 91, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

96. (New) The method of Claim 92, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

97. (New) The method of Claim 93, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

Appl. No. : **10/719,619**
Filed : **November 20, 2003**

98. (New) The method of Claim 90, wherein said viral antigen comprises a hepatitis C viral antigen.

99. (New) The method of Claim 91, wherein said viral antigen comprises a hepatitis C viral antigen.

100. (New) The method of Claim 92, wherein said viral antigen comprises a hepatitis C viral antigen.

101. (New) The method of Claim 93, wherein said viral antigen comprises a hepatitis C viral antigen.

102. (New) The method of Claim 90, wherein said viral antigen comprises an NS3 antigen.

103. (New) The method of Claim 91, wherein said viral antigen comprises an NS3 antigen.

104. (New) The method of Claim 92, wherein said viral antigen comprises an NS3 antigen.

105. (New) The method of Claim 93, wherein said viral antigen comprises an NS3 antigen.

106. (New) The method of Claim 90, wherein said viral antigen comprises an NS4A antigen.

Appl. No. : **10/719,619**
Filed : **November 20, 2003**

107. (New) The method of Claim 91, wherein said viral antigen comprises an NS4A antigen.

108. (New) The method of Claim 92, wherein said viral antigen comprises an NS4A antigen.

109. (New) The method of Claim 93, wherein said viral antigen comprises an NS4A antigen.

110. (New) A method of producing a T cell response to a hepatitis viral antigen in a subject in need thereof consisting essentially of providing, in a single administration, an immunogenic composition that comprises an effective amount of ribavirin and said hepatitis viral antigen to said subject.

111. (New) The method of Claim 110, further comprising identifying said subject as one in need of a T cell response to said hepatitis viral antigen.

112. (New) The method of Claim 110, further comprising measuring the T cell response to said hepatitis viral antigen.

113. (New) The method of Claim 111, further comprising measuring the T cell response to said hepatitis viral antigen.

114. (New) The method of Claim 110, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

115. (New) The method of Claim 111, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

Appl. No. : **10/719,619**
Filed : **November 20, 2003**

116. (New) The method of Claim 112, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

117. (New) The method of Claim 113, wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.

118. (New) The method of Claim 110, wherein said viral antigen comprises a hepatitis C viral antigen.

119. (New) The method of Claim 111, wherein said viral antigen comprises a hepatitis C viral antigen.

120. (New) The method of Claim 112, wherein said viral antigen comprises a hepatitis C viral antigen.

121. (New) The method of Claim 113, wherein said viral antigen comprises a hepatitis C viral antigen.

122. (New) The method of Claim 110, wherein said viral antigen comprises an NS3 antigen.

123. (New) The method of Claim 111, wherein said viral antigen comprises an NS3 antigen.

124. (New) The method of Claim 112, wherein said viral antigen comprises an NS3 antigen.

125. (New) The method of Claim 113, wherein said viral antigen comprises an NS3 antigen.

Appl. No. : **10/719,619**
Filed : **November 20, 2003**

126. (New) The method of Claim 110, wherein said viral antigen comprises an NS4A antigen.

127. (New) The method of Claim 111, wherein said viral antigen comprises an NS4A antigen.

128. (New) The method of Claim 112, wherein said viral antigen comprises an NS4A antigen.

129. (New) The method of Claim 113, wherein said viral antigen comprises an NS4A antigen.

130. (New) The method of Claim 90, wherein said immunogenic composition is provided to said subject transdermally.

131. (New) The method of Claim 90, wherein said immunogenic composition is provided to said subject intranasally.

132. (New) The method of Claim 110, wherein said immunogenic composition is provided to said subject transdermally.

133. (New) The method of Claim 110, wherein said immunogenic composition is provided to said subject intranasally.

134. (New) The method of Claim 90, wherein said immunogenic composition comprises an oil.

135. (New) The method of Claim 110, wherein said immunogenic composition comprises an oil.

Appl. No. : **10/719,619**
Filed : **November 20, 2003**

136. (New) The method of Claim 90, wherein said immunogenic composition is formulated for use with an injection device.

137. (New) The method of Claim 136, wherein said injection device is an electrical injection device.

138. (New) The method of Claim 136, wherein said injection device is a needleless injection device.

139. (New) The method of Claim 110, wherein said immunogenic composition is formulated for use with an injection device.

140. (New) The method of Claim 139, wherein said injection device is an electrical injection device.

141. (New) The method of Claim 139, wherein said injection device is a needleless injection device.